Most Read Articles
Audrey Abella, 04 Jul 2018
The addition of the sodium-glucose linked transporter-2 inhibitor ipragliflozin to insulin resulted in more body weight and fat mass reduction as well as better glucose control than insulin alone in patients with type 2 diabetes (T2D) with weight gain issues, according to a Japanese trial presented at ADA 2018.
10 Oct 2017
Use of canagliflozin in the treatment of type 2 diabetes mellitus (T2DM) leads to greater reductions in glycosylated haemoglobin (HbA1c) and improved medication persistence when compared with sitagliptin, according to a study.
17 Apr 2019
Non-alcoholic fatty liver disease (NAFLD) – a clinicopathological spectrum comprising hepatic steatosis or non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) – is the hepatic manifestation of metabolic syndrome recognized as a leading cause of liver morbidity and mortality. Dr Loo Wai Mun, Consultant at the Division of Gastroenterology and Hepatology, National University Hospital, Singapore, speaks with Audrey Abella to discuss how NAFLD can be best managed in primary care.
Audrey Abella, 26 Sep 2017
The novel, G-protein coupled receptor 119 (GPR119) agonist DS-8500a demonstrated dose-dependent glucose-lowering effects and favourable improvements in lipid parameters that extended up to 12 weeks in Japanese patients with type 2 diabetes mellitus (T2D), according to data presented at EASD 2017.

Product Highlight - Clipax

29 Nov 2019
• First-line chemotherapy of ovarian cancer, CLIPAX is indicated for the treatment of patients with advanced disease or residual disease (>1 cm) after initial laparotomy, in combination with Cisplatin.

• Second line chemotherapy of ovarian cancer, CLIPAX is indicated in the treatment of metastatic carcinoma of the ovary after failure of standard platinum based therapy.

• In the adjuvant setting, CLIPAX is indicated for the treatment of patients with node-positive breast carcinoma following anthracycline and Cyclophosphamide (AC) therapy.

• CLIPAX in combination with Cisplatin, is indicated for the treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgical intervention and/or radiation therapy.



Reference:
Clipax Full Prescribing Information.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Philippines digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 04 Jul 2018
The addition of the sodium-glucose linked transporter-2 inhibitor ipragliflozin to insulin resulted in more body weight and fat mass reduction as well as better glucose control than insulin alone in patients with type 2 diabetes (T2D) with weight gain issues, according to a Japanese trial presented at ADA 2018.
10 Oct 2017
Use of canagliflozin in the treatment of type 2 diabetes mellitus (T2DM) leads to greater reductions in glycosylated haemoglobin (HbA1c) and improved medication persistence when compared with sitagliptin, according to a study.
17 Apr 2019
Non-alcoholic fatty liver disease (NAFLD) – a clinicopathological spectrum comprising hepatic steatosis or non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) – is the hepatic manifestation of metabolic syndrome recognized as a leading cause of liver morbidity and mortality. Dr Loo Wai Mun, Consultant at the Division of Gastroenterology and Hepatology, National University Hospital, Singapore, speaks with Audrey Abella to discuss how NAFLD can be best managed in primary care.
Audrey Abella, 26 Sep 2017
The novel, G-protein coupled receptor 119 (GPR119) agonist DS-8500a demonstrated dose-dependent glucose-lowering effects and favourable improvements in lipid parameters that extended up to 12 weeks in Japanese patients with type 2 diabetes mellitus (T2D), according to data presented at EASD 2017.